In CML, the efficacy of NK-128 is likely high because AMPK activation promotes translocation of the BCR::ABL protein to the cytoplasm, followed by autophagic degradation, in CML cells. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.